NCT00860977

Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?

VALacyclovir In Delaying Antiretroviral Treatment Entry

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 202 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicentre, randomized, placebo-controlled, fully blinded, clinical trial of twice daily oral valacyclovir 500mg versus placebo with the goal of delaying the need for initiating HAART among HIV infected individuals who neither use nor require HAART, and who have not used chronic suppressive anti-HSV therapy for at least the 6 months prior to study initiation.

Conditions

• HIV Infection
• Herpes Simplex Type II
• HIV Infections

Interventions

Type	Name	Description
DRUG	valacyclovir	oral valacyclovir 500mg twice daily
DRUG	Placebo	Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily

Timeline

• Start date: 2010-03-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2009-03-13
• Last updated: 2018-03-06

Locations

25 sites across 4 countries: Argentina, Brazil, Canada, United Kingdom